Please see the attached correspondence sent from the World Health Organization, Regional
Office for Europe. One or more attachments may be included.
Veuillez vous référer à la correspondance ci-jointe du Bureau régional de l'Europe de
l'Organisation mondiale de la santé. Une ou plusieurs annexes peuvent être jointes.
Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen),
Weltgesundheitsorganisation, Regionalbüro für Europa.
См. прикрепленные письма от Европейского р
егионального бюро Всемирной организации з
дравоохранения (один или несколько прикреп
ленных файлов).
Measles and Rubella National Reference Laboratory
Check-list for WHO Accreditation
Section 1: General Review & Overall Findings
Dates of 01/01/2017 - On-site / Desk Review Accreditation for
Review: 31/12/2017 calendar year: 2019
Name of Laboratory of Communicable Diseases, Health Board
Laboratory:
Address: Paldiski mnt 81, 10617 Tallinn
Country Estonia
Phone: +3727943 671 Email:
[email protected] Website: www.terviseamet.
+3727943 635 grete- ee
[email protected]
Head of Institute: Merike Jürilo Head of Department: Külli Rae
Head of Measles and Grete-Katariine Kuum
Rubella Laboratory:
Technical Supervisor: Grete-Katariine Kuum
Number of laboratories under supervision: 1
Name of
Reviewer(s): Dr. Myriam Ben Mamou & Dovile Videbaek, WHO EURO
Name of National Accreditation Authority (if appropriate) and current accreditation status from this
authority (e.g. ISO15189 or other, provide documentation):
Estonian Accreditation Centre certified on 30.06.2014 that Communicable Diseases Laboratory for
HB has competence according to ISO 15189:2007 as a medical laboratory to conduct researches in
the field of clinical and microbiological research. The accreditation shall remain in effect until
29.06.2019.
1
Summary of Accreditation Review
Recommendations (check one):
Accredit: Laboratory meets all criteria
Measles: Rubella:
Serology Serology
Detection RT-PCR/RT-qPCR Detection RT-PCR/RT-qPCR
Sequencing Sequencing
Cell Culture Cell Culture
Measles testing not done Rubella testing not done
Provisionally accredit: Laboratory passed the most recent proficiency test, but needs to
strengthen one or more of the remaining criteria (check off relevant criteria):
Measles: Rubella:
Serology Serology
Detection RT-PCR/RT-qPCR Detection RT-PCR/RT-qPCR
Sequencing Sequencing
Cell Culture Cell Culture
Measles testing not done Rubella testing not done
Do not accredit: Laboratory did not pass the most recent proficiency test and/or did not meet
other performance indicators.
Measles: Rubella:
Serology Serology
Detection RT-PCR/RT-qPCR Detection RT-PCR/RT-qPCR
Sequencing Sequencing
Cell Culture Cell Culture
Measles testing not done Rubella testing not done
2
Main General Findings:
Findings:
Measles and rubella IgM test results are reported by the laboratory to Measles: 98%
1.
the surveillance system within 4 days for ≥ 80% of specimens: Rubella: 92%
Measles: 122
2. IgM tests are performed on at least 50 specimens annually:
Rubella: 126
The laboratory reports to MRLDMS and/or to CISID monthly (WHO Completeness: 92%
3.
Regional Office) Timeliness: 92%
Internal quality control (QC) procedures for serology and molecular diagnostics are
4.
implemented:
Measles: 100%
5. The accuracy of IgM detection is ≥ 90% (20 measles and 25 rubella samples)
Rubella: 100%
Score on most recent WHO Serology proficiency test is ≥ 90%: Measles: 96.77%
6.
PT panel number: 01701 Date reported: 11/09/2017 Rubella: 96.13%
Performance on most recent WHO Molecular EQA (if
Measles Mol detection:
appropriate) is passed (P) /re-test (R), provisionally passed)/fail
Measles Sequencing:
7. (F) NA
Panel for measles: Date reported: Rubella Mol detection:
Panel for rubella: Date reported: Rubella Sequencing:
Virus genotyping (if performed) is completed AND data reported to
8. WHO through MeaNS or RubeNS within 2 months of receipt of specimens, MeaNS: NA
for ≥80% of the specimens appropriate for genetic analysis: RubeNS:
9. Score from on-site review of laboratory operating procedures and practices is ≥ 80%:
Key accreditation criteria
6- Careful attention should be paid to all the criteria involved in final score calculation to
avoid a reduced performance (in-house controls should be used and results should be
reported in 14 days of receipt of the panel).
Conclusion
• Good performance.
3